The biotechnology company will share key scientific findings from its research portfolio at the EAACI 2025 Congress, including preliminary clinical proof of concept for its peanut allergy vaccine candidate and data on its Grass MATA MPL immunotherapy.
The biotechnology company announces the winner of a research award in collaboration with the European Academy of Allergy and Clinical Immunology.
The biotechnology firm reported improved H1 results with revenue growth and reduced losses. Clinical progress in key allergy treatments was highlighted, but ongoing funding needs remain a concern.
The biotechnology company specialising in allergy immunotherapies has advanced its innovative peanut allergy vaccine candidate to the final phase of a clinical trial, with healthy volunteers receiving the highest doses and no safety signals observed.
The biotechnology company has granted new long-term incentive awards to its senior executives and share options to all other employees.
The biotechnology company will be sharing key scientific findings from its pollen and food-allergy research portfolio at the upcoming medical conference.
The biotechnology company announces positive Phase III trial results for its grass pollen allergy treatment, demonstrating significant efficacy improvements over placebo.
The biotechnology company has granted share options to key members of its management team, aligning their interests with shareholders.
The biotechnology company reports revenue growth in the first half, with a recovery in manufacturing capacity and strengthened cash position following new financing facilities.
Routine regulatory update from a commercial biotech company, no major business impact.